Peripheral T-Cell

Ancillaries

Systemic Treatment with Curative Intent

VAR0174
Leveraging Mindsets to Improve Health & Wellbeing in Patients with Cancer
PI: Crum Stanford

Untreated

ENKT cell

LYMNH0154
Phase II Pilot Pembrolizumab in Untreated Extranodal, NK/T Cell Lymphoma, Nasal Type
PI: Advani Stanford

Previously Treated (excluding: Mycosis Fungoides or ALCL)

CXCL12+ tumor

LYMNH0130
Phase II Tipifarnib in Relapsed or Refractory Peripheral T-Cell Lymphoma
PI: Advani Kura Oncology

KIR3DL2 + tumor

LYMNH0151
Phase II IPH4102 +/- Chemotherapy in Advanced T-cell Lymphoma
PI: Kim Sponsor: Pending

KEY

Pending
Open for Enrollment
Observational Study
Optional Path
Trial Posting
Extension Study
Immunotherapy
Enrollment on Hold

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu